ResearcherNewYork–Presbyterian HospitalActive in the last 2 years

Karie D. Runcie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0598-7663; OpenAlex author ID A5051756779. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper

Papers 1

Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae200 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yvonne M. Saenger · 1 shared paper, 2025 · strength 0.28
- Paper Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. DOI 10.1093/oncolo/oyae200 ↗
Tamas A. Gonda · 1 shared paper, 2025 · strength 0.28
- Paper Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. DOI 10.1093/oncolo/oyae200 ↗
Gulam Abbas Manji · 1 shared paper, 2025 · strength 0.28
- Paper Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. DOI 10.1093/oncolo/oyae200 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.